∞ ALBERTA PRECISION LABORATORIES Leaders in Laboratory Medicine

Special Coagulation Testing Requisition Hemostasis Investigations

Scanning Label or Accession # (lab only)

For detailed testing information, refer to

APL Test Directory (http://ahsweb.ca/lab/apl-td-lab-test-directory)						ory)			
	PHN Expiry:			Date of Birth (dd					
ent	Legal Last Name		Legal First Name		Middle	Middle Name			
Patient	Alternate Identifier Preferred		Name	☐ Male ☐ Non-binary	☐ Female ☐ Prefer not t	o disclose	Phone		
Provider(s)	Address		City/Town		Prov		Postal Code		
	Authorizing Provider Name (last, first, midd		lle)	Copy to Nam	Copy to Name (last, first, middle)		Copy to Name (last, first, middle)		
	Address		Phone	Address		Address			
ovic	CC Provider ID CC Su		bmitter ID	Legacy ID	Phone	Phone		Phone	
4	Clinic Name			Clinic Name		Clinic I	Clinic Name		
C	ollection	ection Date (dd-Mon-yyyy)		Time (24 hr)	Location		Collect	Collector ID	
	DO NOT USE THIS REQUISITION FOR ROUTINE COAGULATION STUDIES (INR, PTT, FIBRINGEN, ANTI-Xa, D-DIMER),								
	ANTIPHOSPHOLIPID ANTIBODY/LUPUS WORKUP OR ADVANCED PLATELET STUDIES. TESTING WILL BE CANCELLED IF REQUISITION IS INCOMPLETE.								
	Is the patient currently on any anticoagulants? (Select all that apply) Last Dose Date (dd-Mon-yyyy)								
	□ None □ Heparin (unfractionated or low-molecular) □ Vitamin K Antagonist (eg. warfarin)								
US	□ Other (eg. apixaban, rivaroxaban, fondaparinux, dabigatran, etc)								
Questions	Has the patient been diagnosed with a bleeding disorder?								
les	□ Yes ► Please specify □ No								
	Does the patient have a family history of bleeding or bleeding disorder? ☐ Yes ► Please specify ☐ No								
Order	Does the patient have a history of bleeding? (Select all that apply) □ No								
₹	☐ Joint ☐ Epistaxis ☐ Peri-operative ☐ Post-operative			☐ Menorrhagia ☐ Skin (petechiae /bruising ye ☐ Post-partum ☐ Other (specify)			ing)	☐ Muscle	
nswer	Has the patient received blood components or plasma derivatives? (Select all that apply) □ No								
Last Dose Date (dd-Mon-yyyy) □ Plasma □ Cryoprecipitate □ Fibrinogen concentrate □ Prothrombin complex concen □ Factor VIII (□ extended half-life) □ Factor IX (□ extended half-life) □ Factor XIII (□ extended half-life) □ Von Willebrand factor/Factor VIII complex □ Anti-inhibitor coagulant complex (e.g. FEIB) □ Recombinant factor VIIa □ Platelets □ Emicizumab □ Other (specify)									
								•	
								implex (c.g. I LIBA)	
	Von Willebrand Disease (vWF) Evaluation								
	□ vWD Screening Evaluation (Includes FVIII activity, vWF antigen and vWF function)								
ed	□ vWF Antigen Only								
lest	Inhibitor Scr	eens	□ PTT In	hibitor Screen	□ PT Inh	nibitor Screen		Lupus Anticoagulant	
Rednested	PTT-Based F □ Factor VIII			IX Activity	☐ Factor	XI Activity		I Factor XII Activity	
t(s)	PT-Based Fa		□ Footo-	\/ A ativity		c \ / II. A officitie		Teator V Astivity	
Test(s)	☐ Factor II Ad			V Activity		VII Activity		I Factor X Activity	
•	Specific Inhil	Ditor Screen	⊔ Factor	VIII Inhibitor	⊔ Factor	r IX Inhibitor	☐ Other		
	Hematologis	t Orderable C	Onlv □ Fa	ctor XIII	omogenic Facto	r VIII Activity	☐ Chrome	ogenic Factor IX Activity	